Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on February 3, 2026, reporting the entry into material definitive agreements involving a capital raise and debt refinancing. The company is a Delaware corporation with principal executive offices in New York, New York.
Key Financial Metrics and Transaction Details
- Capital Raised: $30 million aggregate purchase price from accredited investors.
- Equity Issued: 30,000 shares of Series D Convertible Preferred Stock and warrants to purchase an additional 30,000 shares.
- Debt Refinancing:
- Redeemed all 16,962 shares of Series C Preferred Stock.
- Refinanced $8,414,890 principal and interest of the 2022 Senior Secured Convertible Note.
- Issued a new 2026 Senior Secured Convertible Note with a principal amount of $15 million.
- Cash Outflow for Refinancing: Approximately $22,346,241 paid to the 2022 Note holder using proceeds from the Series D offering.
- Debt Terms (2026 Note): 15.0% annual interest rate, payable quarterly; matures February 3, 2029.
- Liquidity Covenants: Required available cash of $5 million (increasing to $8 million after July 1, 2026).
Material Changes Versus Prior Period
The filing details a significant restructuring of the company's capital structure compared to the prior period:
- Debt Reduction: The principal obligation of the 2022 Note ($8.4 million) was replaced by a larger $15 million 2026 Note, though the total cash outlay to settle the old debt was approximately $22.3 million.
- Equity Structure: Introduction of Series D Preferred Stock, which ranks senior to Common Stock and pari passu with Series B Preferred Stock.
- Ownership Rights: Series D holders gain the right to appoint one director and possess protective voting provisions.
- Subsidiary Equity Grant: The 2022 Note holder was granted 300,000 shares of Lucid Diagnostics Inc. (subsidiary) common stock upon maturity or earlier termination of the 2026 Note.
Guidance, Outlook, Risks, and Unusual Items
- Stockholder Approval: The company must hold a special stockholder meeting by April 30, 2026, to approve the issuance of common stock upon conversion of Series D Preferred Stock in excess of Nasdaq primary market limitations.
- Warrant Call Right: Warrants are callable by the company at $0.001 per share if the Esoguard product receives a draft local coverage determination for Medicare coverage (no earlier than February 28, 2026).
- Redemption Risks:
- Series D: Holders may redeem shares for 300% to 500% of stated value starting February 3, 2029, or earlier upon a "Triggering Event" (e.g., bankruptcy or Event of Default on the 2026 Note).
- 2026 Note: Subject to "Make-Whole" redemption provisions and 115% redemption upon an Event of Default.
- Key Personnel Risk: The 2026 Note defines an Event of Default if Lishan Aklog, M.D. (CEO) or Dennis McGrath (CFO) cease to serve in their respective roles.
- Financial Covenants: The company must maintain a specific ratio between the 2026 Note value and the average VWAP of Lucid common stock held by the company (not exceeding 65%, dropping to 50% after July 1, 2026).
Investor Verification Checklist
- Verify the outcome of the special stockholder meeting scheduled for or before April 30, 2026, regarding the conversion of Series D Preferred Stock.
- Monitor the status of the Esoguard product's Medicare coverage determination, which triggers the call right on warrants.
- Confirm the company's ability to meet the $5 million (and later $8 million) available cash covenant under the 2026 Note.
- Review the valuation of Lucid Diagnostics Inc. common stock held by Pavmed to ensure compliance with the debt-to-equity ratio covenant.
- Assess the impact of the 15% interest rate on the $15 million 2026 Note on future cash flow requirements.